Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

Evotec Ag (Adr) ( (EVO) ) has released its Q3 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Analyst Brendan Smith of TD Cowen maintained a Buy rating on Evotec AG (EVO – Research Report), with a price target of $10.00. Brendan ...

Evotec agreed to sell its chemical API production facility ... Canadian drugmaker Apotex hired banks to prepare for its IPO.

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...

HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (MDAX/TecDAX, ISIN: DE0005664809) (NASDAQ:EVO) today announced its financial results and corporate updates ...

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. Triton's other investments range from pharmaceutical companies Bormioli Pharma and Clinigen to tank ...

HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange ... m New technology development partnership with Novo Nordisk to support next-generation cell therapies ...